Up next

Autoplay

Dr. David Crawford Compares Degarelix and LHRH Agonists

2 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

E. David Crawford, MD, professor in Surgery and Radiation Oncology and the head of Urologic Oncology at the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

To view more prostate cancer resources, visit http://www.onclive.com/specialty/prostate-cancer

Show more
0 Comments sort Sort By

Up next

Autoplay